Metastatic Hormone-Sensitive Prostate Cancer: When to Use Doublet vs Triplet Systemic Therapy

Authored by Natalia Gandur, published on 2026-07-24 19:46:58.0

This algorithm is designed to guide first-line treatment selection in metastatic hormone-sensitive prostate cancer (mHSPC), focusing specifically on the decision between ADT + ARPI versus ADT + docetaxel + ARPI. It avoids duplicating a broad metastatic prostate cancer pathway and instead focuses on patient selection for doublet versus triplet systemic therapy.Broadly aligned with current standard management of mHSPC: treatment intensification beyond ADT alone for most patients, with selection of doublet (ADT+ARPI) versus triplet (ADT+docetaxel+ARPI) based on disease volume/risk, de novo vs metachronous presentation, symptoms/visceral disease, and chemotherapy fitness. The strongest evidence for triplet is in de novo high-volume/high-risk, docetaxel-fit patients (ARASENS; PEACE-1). The emphasis on ADT+ARPI for lower-volume and/or metachronous disease is consistent with major guidelines and multiple pivotal ARPI trials. Prostate radiotherapy for de novo low-volume disease is supported by randomized data, though integration with systemic intensification continues to evolve.

  1. Confirmed mHSPC (Start ADT backbone)
    ADT is the foundational backbone for mHSPC systemic therapy; all intensification strategies in current guidelines and pivotal trials are built on continuous ADT.
    • Assess Key Variables
      Disease timing: de novo vs metachronous Disease burden: high-volume vs low-volume Disease risk: high-risk vs low-risk Visceral metastases / symptoms ECOG / docetaxel fitness Frailty, comorbidities, access, patient preference
      • Aggressive disease and fit for docetaxel?
        Docetaxel added to ADT improves survival particularly in high-volume mHSPC and is reserved for patients with adequate performance status and organ reserve; meta-analytic patient-level data refine who benefits most.
        • YES
          • Triplet Therapy Favored
            De novo high-volume and/or high-risk disease Visceral metastases or marked symptoms ECOG 0–1, docetaxel-fit Use when chemotherapy is feasible and accepted Examples: ADT + docetaxel + darolutamide ADT + docetaxel + abiraterone/prednisone
            • Special situation: De novo low-volume disease*
              *Favor ADT + ARPI and separately consider prostate radiotherapy.
        • NO
          • Doublet Therapy Favored
            Low-volume disease Metachronous recurrence Frailty, comorbidities, or docetaxel-unfit Preference to avoid chemotherapy / logistical barriers Examples: ADT + abiraterone/prednisone ADT + enzalutamide ADT + apalutamide ADT + darolutamide (where available)
            • Special situation: De novo low-volume disease*
              *Favor ADT + ARPI and separately consider prostate radiotherapy.
  2. Key Take-Home Points
    Avoid ADT alone when combination therapy is feasible Strongest triplet signal: de novo high-volume/high-risk, docetaxel-fit disease Strongest doublet signal: low-volume and/or metachronous disease
tosprivacyNCCN Prostate Cancer Guidelines Version 5.2026EAU Prostate Cancer Guidelines 2025Prostate Cancer Guidelines: Guidelines SummaryProstate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In OncologyAdvanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialWhich patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trialsUromigos Episode 493: The Role of Chemotherapy in mHSPCAbiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial designDarolutamide and Survival in Metastatic, Hormone-Sensitive Prostate CancerDarolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS TrialTestosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialApalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN StudyAbiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trialAbiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyDarolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE TrialParker CC, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed Metastatic Prostate Cancer (STAMPEDE)Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysisUromigos Episode 496: APCCC 2026 - mHSPC Landscape